IS2682B - Lyfjablöndur á föstu formi sem fela í sér S1P viðtakaörva og sykuralkóhól - Google Patents

Lyfjablöndur á föstu formi sem fela í sér S1P viðtakaörva og sykuralkóhól

Info

Publication number
IS2682B
IS2682B IS8114A IS8114A IS2682B IS 2682 B IS2682 B IS 2682B IS 8114 A IS8114 A IS 8114A IS 8114 A IS8114 A IS 8114A IS 2682 B IS2682 B IS 2682B
Authority
IS
Iceland
Prior art keywords
solid form
receptor agonists
sugar alcohols
form preparations
preparations
Prior art date
Application number
IS8114A
Other languages
English (en)
Icelandic (is)
Other versions
IS8114A (is
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2682(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of IS8114A publication Critical patent/IS8114A/is
Publication of IS2682B publication Critical patent/IS2682B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IS8114A 2003-04-08 2005-11-01 Lyfjablöndur á föstu formi sem fela í sér S1P viðtakaörva og sykuralkóhól IS2682B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (2)

Publication Number Publication Date
IS8114A IS8114A (is) 2005-11-01
IS2682B true IS2682B (is) 2010-10-15

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
IS8114A IS2682B (is) 2003-04-08 2005-11-01 Lyfjablöndur á föstu formi sem fela í sér S1P viðtakaörva og sykuralkóhól
IS8885A IS8885A (is) 2003-04-08 2010-02-25 Lyfjablanda á föstu formi til til inntöku sem felur í sér S1P viðtakaörva og sykuralkóhól

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8885A IS8885A (is) 2003-04-08 2010-02-25 Lyfjablanda á föstu formi til til inntöku sem felur í sér S1P viðtakaörva og sykuralkóhól

Country Status (41)

Country Link
US (11) US20060275357A1 (OSRAM)
EP (5) EP2008650A3 (OSRAM)
JP (3) JP5495467B2 (OSRAM)
KR (3) KR20050121712A (OSRAM)
CN (2) CN101797241B (OSRAM)
AR (3) AR043987A1 (OSRAM)
AT (3) ATE414508T1 (OSRAM)
AU (1) AU2004228929B2 (OSRAM)
BE (2) BE1015972A5 (OSRAM)
BR (1) BRPI0409250B8 (OSRAM)
CA (2) CA2707750A1 (OSRAM)
CL (2) CL2004000745A1 (OSRAM)
CY (3) CY1110260T1 (OSRAM)
DE (4) DE122011100047I1 (OSRAM)
DK (2) DK1613288T3 (OSRAM)
EC (1) ECSP056090A (OSRAM)
ES (3) ES2556947T3 (OSRAM)
FR (2) FR2854073B1 (OSRAM)
GB (1) GB2400318B (OSRAM)
GR (1) GR1005052B (OSRAM)
HR (3) HRP20050886B1 (OSRAM)
HU (2) HUE028247T2 (OSRAM)
IL (3) IL170888A (OSRAM)
IS (2) IS2682B (OSRAM)
IT (1) ITMI20040682A1 (OSRAM)
LU (1) LU91867I2 (OSRAM)
MA (1) MA27729A1 (OSRAM)
MX (1) MXPA05010860A (OSRAM)
MY (1) MY141249A (OSRAM)
NO (4) NO329332B1 (OSRAM)
NZ (3) NZ592339A (OSRAM)
PE (5) PE20090743A1 (OSRAM)
PL (2) PL1613288T3 (OSRAM)
PT (1) PT1613288E (OSRAM)
RU (5) RU2358716C2 (OSRAM)
SG (1) SG175449A1 (OSRAM)
SI (2) SI1613288T1 (OSRAM)
TN (1) TNSN05256A1 (OSRAM)
TW (1) TWI332847B (OSRAM)
WO (1) WO2004089341A1 (OSRAM)
ZA (1) ZA200507394B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993115B (zh) * 2004-07-30 2011-12-28 诺瓦提斯公司 2-氨基-1,3-丙二醇化合物的制剂
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
SI1926483T1 (sl) * 2005-09-09 2011-04-29 Novartis Ag Zdravljenje avtoimunskih bolezni
ES2628620T3 (es) 2005-11-09 2017-08-03 Onyx Therapeutics, Inc. Compuesto para inhibición de enzimas
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MX2008016512A (es) 2006-06-19 2009-02-26 Proteolix Inc Epoxicetonas peptidicas para la inhibicion del proteasoma.
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
MX2020001259A (es) * 2006-09-26 2020-03-20 Novartis Ag Composiciones farmaceuticas que comprenden un modulador de s1p.
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
NZ579725A (en) 2007-03-29 2012-02-24 Daiichi Sankyo Co Ltd Tablet composition having improved dissolution property
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP2209493A2 (en) * 2007-10-12 2010-07-28 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
EP2278960B2 (en) 2008-03-17 2019-11-13 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
KR101647855B1 (ko) * 2008-06-20 2016-08-11 메르크 파텐트 게엠베하 직접 사출성형가능한 신속 붕해 정제 매트릭스
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
CA2735037C (en) * 2008-09-04 2016-07-12 Cargill Incorporated Tabletting of erythritol
EP2349313A4 (en) 2008-10-21 2012-08-29 Onyx Therapeutics Inc COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
ES2643161T3 (es) 2008-11-11 2017-11-21 Novartis Ag Formas cristalinas de HCL de fingolimod
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
EP2358660A2 (en) 2008-11-11 2011-08-24 Novartis AG Salts of fingolimod
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
WO2010104078A1 (ja) 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2010147169A1 (ja) * 2009-06-18 2010-12-23 第一三共株式会社 溶出性の改善された医薬組成物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
JP6042724B2 (ja) 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
ES2560955T3 (es) 2010-03-19 2016-02-23 Daiichi Sankyo Company, Limited Cristal de derivado de diamina y procedimiento de producción del mismo
CN102791271B (zh) 2010-03-19 2014-05-14 第一三共株式会社 抗凝剂的溶出改善方法
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
CN103080078B (zh) 2010-07-02 2015-02-11 第一三共株式会社 光学活性二胺衍生物盐的制备方法
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMOD POLYMORPHES AND METHOD THEREFOR
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
ES2662373T3 (es) 2011-01-19 2018-04-06 Pathologica, Llc. Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2739272A1 (en) * 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
BR112015016189A8 (pt) 2013-01-08 2019-10-22 Pathologica Llc usos de metilglioxal bis (guanilhidrazona) (“mgbg”), uso de metilglioxal bis (guanilhidrazona) (“mgbg”) e um agente e composição farmacêutica
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
US9629834B2 (en) * 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
TW202245741A (zh) * 2021-01-28 2022-12-01 法商普萊歐塞拉公司 使用s1p受體調節劑之治療方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2171191T3 (es) 1994-08-22 2002-09-01 Mitsubishi Pharma Corp Compuesto de benceno y uso medicinal del mismo.
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ES2317663T3 (es) * 1997-02-27 2009-04-16 Novartis Ag Composicion farmaceutica que comprende 2-amino-2-(2-(4-octilfenil)etil)propano-1,3-diol, una lecitina y un sacarido.
EP1319651B1 (en) * 1997-04-04 2005-06-29 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
ATE360011T1 (de) 2000-07-13 2007-05-15 Sankyo Co Aminoalkoholderivate
JP2004507552A (ja) * 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
CZ20032560A3 (cs) 2001-03-26 2003-12-17 Novartis Ag Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
EP1470137B1 (en) 2002-01-18 2009-09-02 Merck & Co., Inc. Edg receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect

Also Published As

Publication number Publication date
WO2004089341A1 (en) 2004-10-21
US20140255497A1 (en) 2014-09-11
IL197578A0 (en) 2011-07-31
CA2707750A1 (en) 2004-10-21
BRPI0409250B1 (pt) 2017-07-11
NO20131287L (no) 2006-01-09
FR11C0036I2 (fr) 2023-12-29
ES2228282B1 (es) 2006-02-16
ES2228282A1 (es) 2005-04-01
PE20131352A1 (es) 2013-11-14
CY1110260T1 (el) 2014-04-09
JP5543298B2 (ja) 2014-07-09
FR11C0036I1 (fr) 2011-10-14
BRPI0409250B8 (pt) 2022-01-18
TNSN05256A1 (en) 2007-07-10
KR101367574B1 (ko) 2014-02-25
IL197578A (en) 2015-10-29
CY1117071T1 (el) 2017-04-05
HUE028247T2 (en) 2016-12-28
TWI332847B (en) 2010-11-11
IL242037A0 (en) 2015-11-30
US20200237690A1 (en) 2020-07-30
GB0407819D0 (en) 2004-05-12
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
CL2004000745A1 (es) 2005-02-11
MA27729A1 (fr) 2006-01-02
FR2854073A1 (fr) 2004-10-29
US20110105620A1 (en) 2011-05-05
US20090203798A1 (en) 2009-08-13
SI2316431T1 (sl) 2016-04-29
AR043987A1 (es) 2005-08-17
LU91867I2 (fr) 2011-11-08
HK1091114A1 (en) 2007-01-12
EP2008650A2 (en) 2008-12-31
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
AR078782A2 (es) 2011-11-30
NO20055231D0 (no) 2005-11-07
EP2008650A3 (en) 2011-04-27
EP1613288A1 (en) 2006-01-11
US20130108675A1 (en) 2013-05-02
NO329332B1 (no) 2010-09-27
NZ586280A (en) 2011-12-22
JP5495467B2 (ja) 2014-05-21
EP2319502A1 (en) 2011-05-11
EP2769713A1 (en) 2014-08-27
EP2316431B1 (en) 2015-09-30
CA2521325A1 (en) 2004-10-21
RU2005134173A (ru) 2006-09-10
ZA200507394B (en) 2007-03-28
IS8885A (is) 2010-02-25
CY2011013I2 (el) 2014-04-09
HRP20100600A2 (hr) 2011-03-31
NZ592339A (en) 2012-09-28
RU2475237C2 (ru) 2013-02-20
RU2475236C2 (ru) 2013-02-20
AU2004228929A1 (en) 2004-10-21
ES2556947T3 (es) 2016-01-21
HRP20050886B1 (en) 2011-01-31
PE20050396A1 (es) 2005-07-05
KR20050121712A (ko) 2005-12-27
PE20090743A1 (es) 2009-07-17
KR20120101148A (ko) 2012-09-12
CN1767819B (zh) 2010-07-28
NO335120B1 (no) 2014-09-22
DK1613288T3 (da) 2009-03-23
NO20100250L (no) 2006-01-09
DE602004017847D1 (de) 2009-01-02
JP2011006461A (ja) 2011-01-13
IS8114A (is) 2005-11-01
RU2012148593A (ru) 2014-05-20
TW200503784A (en) 2005-02-01
DK2316431T3 (en) 2016-01-11
IL170888A (en) 2010-06-16
AT501681B1 (de) 2012-04-15
ATE414508T1 (de) 2008-12-15
NO2011016I2 (no) 2012-08-27
KR20110005320A (ko) 2011-01-17
RU2009105403A (ru) 2010-08-27
HRP20100601B1 (hr) 2016-12-02
GB2400318B (en) 2005-08-10
DE102004016947A1 (de) 2004-10-21
PT1613288E (pt) 2009-02-25
US20140011885A1 (en) 2014-01-09
AR078781A2 (es) 2011-11-30
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
ECSP056090A (es) 2006-03-01
GB2400318A (en) 2004-10-13
CN101797241B (zh) 2013-03-27
NO2011016I1 (no) 2011-09-19
IE20040246A1 (en) 2004-12-15
ITMI20040682A1 (it) 2004-07-06
RU2010147000A (ru) 2012-08-10
BRPI0409250A (pt) 2006-03-28
DE122011100047I1 (de) 2011-12-15
GR20040100121A (el) 2004-12-17
HRP20050886A2 (en) 2006-11-30
LU91867I9 (OSRAM) 2019-01-03
PE20130200A1 (es) 2013-03-09
US8324283B2 (en) 2012-12-04
AU2004228929B2 (en) 2008-02-07
NO334116B1 (no) 2013-12-16
NZ542622A (en) 2009-01-31
SI1613288T1 (sl) 2009-04-30
RU2010146697A (ru) 2012-05-27
HK1155647A1 (en) 2012-05-25
CY2011013I1 (el) 2014-04-09
PE20150676A1 (es) 2015-05-17
US20220031609A1 (en) 2022-02-03
FR2854073B1 (fr) 2008-03-14
JP2013177404A (ja) 2013-09-09
GR1005052B (el) 2005-11-30
JP2004307506A (ja) 2004-11-04
CN1767819A (zh) 2006-05-03
SG175449A1 (en) 2011-11-28
ES2320767T3 (es) 2009-05-28
US20190175527A1 (en) 2019-06-13
PL1613288T3 (pl) 2009-07-31
AT501681A1 (de) 2006-10-15
RU2358716C2 (ru) 2009-06-20
HUS1100016I1 (hu) 2016-08-29
BE2011C030I2 (OSRAM) 2023-03-07
HRP20100601A2 (hr) 2011-03-31
US20170290787A1 (en) 2017-10-12
MXPA05010860A (es) 2006-05-25
CA2521325C (en) 2010-09-14
CN101797241A (zh) 2010-08-11
US20080311188A1 (en) 2008-12-18
MY141249A (en) 2010-03-31
AT504853A2 (de) 2008-08-15
EP1613288B1 (en) 2008-11-19
US20060275357A1 (en) 2006-12-07
DE202004021680U1 (de) 2010-04-22

Similar Documents

Publication Publication Date Title
IS2682B (is) Lyfjablöndur á föstu formi sem fela í sér S1P viðtakaörva og sykuralkóhól
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
DE69934831D1 (de) MULTIPLEXES, FüR DIE ORALE VERBABREICHUNG GEEIGNETES MEDIKAMENTENABGABESYSTEM
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
PL378338A1 (pl) Kompozycja do podawania doustnego zawierająca kapsaicynoidy
NO20042272L (no) Farmasoytiske blandinger og fremgangsmater for administrering av EP2-reseptor selektive agonister
ATE348599T1 (de) Pharmazeutische dronedaron-zusammensetzung für die parenterale verabreichung
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
WO2004012722A3 (en) Bicifadine formulation
WO2008060546A3 (en) Oral formulations
AU2003245033A1 (en) An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
IS4942A (is) Ný lyfjablanda til inngjafar um slímu í munnholi,sérstaklega um nef
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
ITMI20020921A0 (it) Dispositivo per la sommistrazione di farmaci
ITMI20010009A0 (it) Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera